Description: ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with high analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal transition; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including enumeration of epithelial and mesenchymal CTC populations; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. ANGLE plc has a strategic partnership with Bio View Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use its proprietary pan-cancer next generation sequencing (NGS) panel. The company was founded in 1994 and is based in Guildford, the United Kingdom.
Home Page: angleplc.com
Surrey Research Park
Guildford,
GU2 7AF
United Kingdom
Phone:
44 14 8334 3434
Officers
Name | Title |
---|---|
Mr. Andrew David William Newland ACA, Meng | Founder, CEO & Executive Director |
Mr. Ian Francis Griffiths ACA, BA | CFO, Finance Director, Company Secretary & Executive Director |
Dr. Karen Miller Ph.D. | Chief Scientific Officer |
Mr. Andrew John Holder | Head of Investor Relations |
Ms. Anne-Sophie Pailhes-Jimenez | Head of R&D and Senior Director |
Mr. Brett Swansiger | Chief Commercial Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 1.1684 |
Price-to-Sales TTM: | 21.659 |
IPO Date: | |
Fiscal Year End: | April |
Full Time Employees: | 150 |